Parian Global Management’s ClearPoint Neuro CLPT Stock Holding History

Parian Global Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,000	Closed	-$317K	–	35
2021 Q3	$317K	Sell	15,000 -60,000	-80%	-$1.13M	0.22%	30
2021 Q2	$1.43M	Buy	+75,000	New	+$1.45M	0.61%	35

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

GPC

Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Parian Global Management's CLPT Position: Q4 2021 in Review

Parian Global Management sold out of ClearPoint Neuro (CLPT) in Q4 2021, closing a stake of 153,950 shares — an estimated $2.73M sold.

Parian Global Management first reported a position in CLPT in Q4 2020 and held it in 4 quarters. The position peaked at $13M in Q2 2021. 67 funds tracked by Wall St. Rank hold CLPT as of Q4 2021.

Parian Global Management reported no remaining ClearPoint Neuro position as of Q4 2021 after selling out during the quarter.
Parian Global Management sold 153,950 ClearPoint Neuro shares in Q4 2021, an estimated $2.73M.
Parian Global Management first reported a position in ClearPoint Neuro in Q4 2020 and held it in 4 quarters.
Parian Global Management's ClearPoint Neuro position peaked at $13M in Q2 2021.
67 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2021.

Based on Parian Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.